| Detailed information |
|---|
| CancerLivER ID | 2019 |
| Biomarker | miR-221 |
| Biomarker Name/Symbol (given in Publication) | miR-221 |
| Biomolecule | miRNA |
| Subject | Human |
| Degree of Validity | Biomarkers for guiding the treatment of liver cancer and for estimating prognosis and validated on independent dataset |
| Experimental Condition | Liver cancer v/s Normal |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in Cancer |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 28781668 |
| Type of Biomarker | Diagnostic and Prognostic |
| Pathway | lymphatic metastasis and TNM staging. |
| Cohort | 70 patients with Liver cancer |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2017 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT02928627 |